Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (141-150 of 201) with videos related to

Pageof 21
Sort By:
Clinical Trials (London, England)|September 29, 2023
Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1Andrea M Gross, Scott R Plotkin, Nelson B Watts, et al.
Molecular Therapy. Methods & Clinical Development|July 18, 2022
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2Shilpa Prabhakar, Roberta L Beauchamp, Pike See Cheah, et al.
Molecular Therapy. Methods & Clinical Development|May 15, 2024
Erratum: Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2Shilpa Prabhakar, Roberta L Beauchamp, Pike See Cheah, et al.
Neurology|November 4, 2022
Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRIK Ina Ly, Vanessa L Merker, Wenli Cai, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 27, 2026
Deciphering and Targeting the Schwannoma-Neuron-Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated PainZhenzhen Yin, Limeng Wu, Yanling Zhang, et al.
Neurology|August 17, 2016
Current status and recommendations for biomarkers and biobanking in neurofibromatosisC Oliver Hanemann, Jaishri O Blakeley, Fabio P Nunes, et al.
Neurology|July 7, 2021
Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2Srivandana Akshintala, Nashwa Khalil, Kaleb Yohay, et al.
Cancer Research|January 5, 2011
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escapeEmmanuelle di Tomaso, Matija Snuderl, Walid S Kamoun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent GlioblastomaElizabeth R Gerstner, Kyrre E Emblem, Ken Chang, et al.
Scientific Reports|November 22, 2018
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
Pageof 21

Showing results (141-150 of 201) with videos related to

Sort By:
Pageof 21
Clinical Trials (London, England)|September 29, 2023
Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1Andrea M Gross, Scott R Plotkin, Nelson B Watts, et al.
Molecular Therapy. Methods & Clinical Development|July 18, 2022
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2Shilpa Prabhakar, Roberta L Beauchamp, Pike See Cheah, et al.
Molecular Therapy. Methods & Clinical Development|May 15, 2024
Erratum: Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2Shilpa Prabhakar, Roberta L Beauchamp, Pike See Cheah, et al.
Neurology|November 4, 2022
Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRIK Ina Ly, Vanessa L Merker, Wenli Cai, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 27, 2026
Deciphering and Targeting the Schwannoma-Neuron-Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated PainZhenzhen Yin, Limeng Wu, Yanling Zhang, et al.
Neurology|August 17, 2016
Current status and recommendations for biomarkers and biobanking in neurofibromatosisC Oliver Hanemann, Jaishri O Blakeley, Fabio P Nunes, et al.
Neurology|July 7, 2021
Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2Srivandana Akshintala, Nashwa Khalil, Kaleb Yohay, et al.
Cancer Research|January 5, 2011
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escapeEmmanuelle di Tomaso, Matija Snuderl, Walid S Kamoun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent GlioblastomaElizabeth R Gerstner, Kyrre E Emblem, Ken Chang, et al.
Scientific Reports|November 22, 2018
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
Pageof 21